ITEMS IN AFP WITH KEYWORD:
Jul 1, 2019 Issue
mSEPT9 (Epi proColon) Blood Test for Colorectal Cancer Screening [Diagnostic Tests: What Physicians Need to Know]
Epi proColon is a blood test used for the detection of the methylated septin 9 (mSEPT9) gene. It is approved by the U.S. Food and Drug Administration for colorectal cancer screening in people at average risk who have declined first-line screening tests.
Over a 10-year period, the rates of detection of colorectal cancer (CRC) and advanced adenomas using FIT are similar to those seen in studies of screening colonoscopy. This does not prove that FIT reduces morbidity and mortality due to CRC as effectively as colonoscopy.
To support early identification and treatment, the American Cancer Society (ACS) has updated its 2008 guidance on counseling and referring patients at average risk of colorectal cancer (CRC) based on new evidence regarding screening options and the ever-changing risk of CRC.
FIT is more sensitive and specific than the older guaiac-based fecal occult blood tests (gFOBTs) when screening for colorectal cancer. We now know that it is also more acceptable to patients and increases uptake in a centrally administered screening program.
Screening for colorectal cancer is recommended in average-risk adults 50 to 75 years of age. Several methods are available, with different benefits, harms, burdens, and costs. Review the options for stool-based screening tests and direct visualization tests, as well as the most effective prevention strategies.
Colorectal cancer has a five-year survival rate of 65%, and family physicians are likely to encounter colorectal cancer survivors in their practice. Learn about the latest guidelines from the American Cancer Society on surveillance, health promotion, screening for other malignancies, and management of treatment effects in these patients.
Persons at increased risk of colorectal cancer should undergo more frequent screening than the general population. Find out recommended screening methods, starting ages, and screening intervals for high-risk individuals.
A 50-year-old woman presents for a routine visit. She is healthy with no significant medical history, takes no medications, and has no personal or family history of cancer.
May 15, 2017 Issue
Should Screening Techniques for Colorectal Cancer All Have an 'A' Recommendation? No: When It Comes to Colorectal Cancer Screening, Test Choice Matters [Editorials: Controversies in Family Medicine]
The AAFP will continue to evaluate different screening tests as more research becomes available, but currently can endorse only those options that have the strongest evidence that benefits exceed harms.
May 15, 2017 Issue
Should Screening Techniques for Colorectal Cancer All Have an 'A' Recommendation? Yes: All Conventional Screening Techniques Should Have an 'A' Recommendation [Editorials: Controversies in Family Medicine]
We need to emphasize the message that regardless of which test is used, patients should get screened for colorectal cancer.